{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:36:29Z","timestamp":1784892989012,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2025GXNSFBA069062"],"award-info":[{"award-number":["2025GXNSFBA069062"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFBA010100"],"award-info":[{"award-number":["2024GXNSFBA010100"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFAA010190"],"award-info":[{"award-number":["2024GXNSFAA010190"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFFA010015"],"award-info":[{"award-number":["2024GXNSFFA010015"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108864","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T22:25:41Z","timestamp":1754778341000},"page":"108864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation"],"prefix":"10.1016","volume":"164","author":[{"given":"Liangping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108864_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108864_bb0010","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bioorg.2025.108864_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102906","article-title":"Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC","volume":"148","author":"Baraibar","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0020","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jtho.2017.06.006","article-title":"Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations","volume":"12","author":"Li","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108864_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0035","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jtho.2019.03.022","article-title":"Advanced-stage non-small cell lung cancer: advances in thoracic oncology 2018","volume":"14","author":"Remon","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/2414897","article-title":"Survival outcomes of nonsmall cell lung cancer patients treated with afatinib who are affected by early adverse events","volume":"2021","author":"Logan","year":"2021","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0045","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108864_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lungcan.2017.04.004","article-title":"Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC","volume":"108","author":"Knebel","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.108864_bb0055","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.18632\/oncotarget.14506","article-title":"Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108864_bb0060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108864_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108864_bb0070","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1158\/1538-7445.AM2019-1320","article-title":"Abstract 1320: preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108864_bb0075","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"C. To","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108864_bb0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/acsmedchemlett.8b00373","article-title":"Discovery of JND3229 as a new EGFR(C797S) mutant inhibitor with in vivo monodrug efficacy","volume":"9","author":"Lu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108864_bb0085","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0090","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1039\/C8SC01262H","article-title":"Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket","volume":"9","author":"Kannan","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.108864_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108864_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108864_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108864_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14517","article-title":"EGFR degraders in non-small-cell lung cancer: breakthrough and unresolved issue","volume":"103","author":"Shen","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108864_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114533","article-title":"Recent advances in the development of EGFR degraders: PROTACs and LYTACs","volume":"239","author":"Hong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/13543776.2023.2262176","article-title":"The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders","volume":"33","author":"Li","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108864_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114509","article-title":"Discovery of highly potent and selective CRBN-recruiting EGFRL858R\/T790M degraders in vivo","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107815","article-title":"Pomalidomide sensitizes lung cancer cells to TRAIL\/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit","volume":"153","author":"Li","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase a drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108864_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4589","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12","author":"Nilsson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108864_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4307","article-title":"Stress hormones promote EGFR inhibitor resistance in NSCLC: implications for combinations with beta-blockers","volume":"9","author":"Nilsson","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108864_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0165","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.6b01912","article-title":"Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds","volume":"61","author":"Chan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108864_bb0175","doi-asserted-by":"crossref","first-page":"16212","DOI":"10.1073\/pnas.0604567103","article-title":"Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2025.108864_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0185","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/15548627.2020.1740529","article-title":"Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux","volume":"17","author":"Kim","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.bioorg.2025.108864_bb0190","doi-asserted-by":"crossref","first-page":"28950","DOI":"10.1074\/jbc.M304474200","article-title":"Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis","volume":"278","author":"Duan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0195","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1101\/gad.12.23.3663","article-title":"C-Cbl\/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor","volume":"12","author":"Levkowitz","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2025.108864_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112199","article-title":"Design and synthesis of selective degraders of EGFRL858R\/T790M mutant","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0210","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsmedchemlett.1c00645","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting del19\/T790M\/C797S mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108864_bb0220","series-title":"HJM-561, a potent, selective, and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple","author":"Du","year":"2025"},{"key":"10.1016\/j.bioorg.2025.108864_bb0225","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bioorg.2025.108864_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105605","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy","volume":"120","author":"Shi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112061","article-title":"Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)","volume":"189","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114455","article-title":"Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0245","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127167","article-title":"Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108864_bb0255","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108864_bb0260","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1021\/acs.jmedchem.1c00373","article-title":"Discovery of a brigatinib degrader SIAIS164018 with destroying metastasis-related oncoproteins and a reshuffling kinome profile","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108864_bb0265","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:31:42Z","timestamp":1762223502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"alternative-id":["S0045206825007448"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108864","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108864"}}